- Home
- AARD vs TTEC Comparison
AARD vs TTEC Comparison
Compare AARD & TTEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AARD
- TTEC
- Stock Information
- Founded
- AARD 2017
- TTEC 1982
- Country
- AARD United States
- TTEC United States
- Employees
- AARD N/A
- TTEC N/A
- Industry
- AARD Biotechnology: Pharmaceutical Preparations
- TTEC Retail: Computer Software & Peripheral Equipment
- Sector
- AARD Health Care
- TTEC Technology
- Exchange
- AARD Nasdaq
- TTEC Nasdaq
- Market Cap
- AARD 154.9M
- TTEC 178.1M
- IPO Year
- AARD 2025
- TTEC 1996
- Fundamental
- Price
- AARD $10.14
- TTEC $5.20
- Analyst Decision
- AARD Strong Buy
- TTEC Buy
- Analyst Count
- AARD 4
- TTEC 4
- Target Price
- AARD $31.50
- TTEC $10.83
- AVG Volume (30 Days)
- AARD 69.4K
- TTEC 334.0K
- Earning Date
- AARD 01-01-0001
- TTEC 05-08-2025
- Dividend Yield
- AARD N/A
- TTEC N/A
- EPS Growth
- AARD N/A
- TTEC N/A
- EPS
- AARD N/A
- TTEC N/A
- Revenue
- AARD N/A
- TTEC $2,165,177,000.00
- Revenue This Year
- AARD N/A
- TTEC N/A
- Revenue Next Year
- AARD N/A
- TTEC N/A
- P/E Ratio
- AARD N/A
- TTEC N/A
- Revenue Growth
- AARD N/A
- TTEC N/A
- 52 Week Low
- AARD $4.88
- TTEC $3.11
- 52 Week High
- AARD $19.58
- TTEC $8.45
- Technical
- Relative Strength Index (RSI)
- AARD N/A
- TTEC 70.38
- Support Level
- AARD N/A
- TTEC $3.72
- Resistance Level
- AARD N/A
- TTEC $5.50
- Average True Range (ATR)
- AARD 0.00
- TTEC 0.31
- MACD
- AARD 0.00
- TTEC 0.14
- Stochastic Oscillator
- AARD 0.00
- TTEC 83.15
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.
About TTEC TTEC Holdings Inc.
TTEC Holdings Inc provides customer engagement management tools and services. The company operates through four operating segments that are organized into two groups, TTEC Digital and TTEC Engage. TTEC Digital is engaged in building and implementing cloud-based and on-premises customer experience tools that enable clients to develop customer engagement strategies. TTEC Engage focuses on delivering sales and marketing solutions to help clients boost their revenue as well as on managing customer's front-to-back office processes to optimize the customer experience. TTEC Engage contributes the vast majority of the company's revenue, and most of the sales are derived from the United States and Canada, followed by Philippines, Asia-Pacific and India.